EXKIVITY™ available from Onco360!
EXKIVITY™ (mobocertinib) is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Dosage Form and Strength1
EXKIVITY is available as 40 mg capsules in 120-count pill bottles (NDC 63020-040-12).
Dosage and Administration
The recommended dose is 160 mg (4 capsules) orally once daily with or without food.
For complete details, visit Exkivity
1Prescribing Information: Takeda Pharmaceuticals America, Inc. EXKIVITY.com accessed 9/21. EXKIVITY™ is a trademark of Takeda Pharmaceuticals International AG.